We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Awards Priority Voucher for Rare Pediatric Disease Designation to Alexion

FDA Awards Priority Voucher for Rare Pediatric Disease Designation to Alexion

November 20, 2015

The FDA has issued Alexion Pharmaceuticals a priority review voucher for a rare pediatric disease designation.

Approved in October, Strensiq (asfotase alfa) is a long-term enzyme replacement therapy to treat infantile and juvenile onset hypophosphatasia, a rare genetic disorder that affects the development of bones and teeth.

With the approval of the drug for the treatment of a rare pediatric disease, the sponsor of the application is eligible for a voucher that can be used to obtain priority review for a subsequent NDA or BLA for another drug.

The vouchers also can be sold to other companies. For example, United Therapeutics agreed to sell its rare pediatric disease priority review voucher to AbbVie for $350 million in August.

The FDA now has issued five rare pediatric disease priority review vouchers. The other four are:

  • BioMarin’s Vimizim (elosulfase alfa) in 2014;
  • Asklepion’s Cholbam (cholic acid) in 2015;
  • United Therapeutics’ Unituxin (dinutuximab) in 2015; and
  • Wellstat’s Xuriden (uridine triacetate) in 2015.

The FDA defines a rare pediatric disease as one that affects fewer than 200,000 individuals under the age of 18.

Alexion spokesperson Kim Diamond says the company expects to use the voucher opportunistically to receive priority review on a future application. 

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing